I present an overview of the management of nonmuscle invasive bladder cancer. The most common intravesical chemotherapeutic agents are described, as well as the impact of chemotherapy on the ...

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of ...

ImmunityBio's stock has risen sharply this year. Read more on whether investors should look closely at shares or avoid the ...

When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cance ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may ...

via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European ...

Matthew Galsky, MD, discusses why some physicians were surprised at the positive outcomes of nivolumab trials in bladder ...

The Food and Drug Administration has approved Padcev plus Keytruda to treat patients with locally advanced or metastatic bladder cancer. The FDA accepted a priority review for the supplemental ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...

Let’s learn about the various types of cancer, their symptoms, causes, and treatment options, as well as about common cancers ...